Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia

International Journal of Nanomedicine

Volumn 1, Issue 3, 2006, Pages 241-254

  Avramis, Vassilios I ^a   Tiwari, Prakash Nidhi ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Antibodies; Asparaginase; Asparagine; Enzymatic activity; Glutamine; Pegylation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; DRUG CARRIER; MACROGOL DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; CHEMISTRY; HUMAN; METABOLISM; REVIEW;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; DRUG CARRIERS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; POLYETHYLENE GLYCOLS;

EID: 34548776939     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Abshire TC, Pollock BH, Billett AL, et al. 2000. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood, 96:1709-15.
2. Albertsen BK, Schroder H, Ingerslev J, et al. 2001. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol, 115:983-90.
3. Albertsen BK, Schroder H, Jakobsen P, et al. 2002. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol, 38:310-16.
4. Appel IM, Pinheiro JP, den Boer ML, et al. 2003. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia, 17:2254-6.
5. Asselin BL, Whitin JC, Coppola DJ, et al. 1993. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol, 11:1780-6.
6. Avramis VI, Mecum RA, Nyce J, et al. 1989. Pharmacodynamics, DNA Methylation studies and clinical response of high-dose 1-ß-D-arabinofuranosylcytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute leukemia. Cancer Chemother Pharmacol, 24:203-10.
7. Avramis VI, Panosyan EH. 2005. Pharmacokinetic-pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. J Clin Pharmacokinetics, 44:367-93.
8. Avramis VI, Sencer S, Periclou AP, et al. 2002. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 99:1986-94.
9. Broome JD. 1961. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its anti-lymphoma effects. Nature, 191:1114-1115.
10. Broome JD. 1963. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its anti-lymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the anti-lymphoma substance. J Exptl Med, 118:99-120.
11. Broome JD. 1965. Antilymphoma activity of L-asparaginase in vivo: clearance rate of enzyme preparations from guinea pig serum and yeast in relation to their effects on tumor growth. J Natl Cancer Inst, 35:967-74.
12. Broome JD. 1981. L-asparaginase: Discovery and development as a tumor-inhibitory agent. Cancer Treat Rep, 65:111-14.
13. Burchenal JH, Karnofsky DA. 1970. Clinical evaluation of L-asparaginase. Cancer. 25:241-3.
14. Capizzi RL. 1993. Asparaginase revisited. Leuk Lymphoma, 10(Suppl):147-50.
15. Capizzi RL, Holcenberg JS. 1993. Asparaginases. In Holland JF (ed). Cancer Medicine. Philadelphia, PA: Lea, Febiger. p 796-805.
16. Chabner BA, Loo TL. 1996. Enzyme therapy: L-asparaginase. In Chabner BA, Longo DL (eds). Cancer chemotherapy and biotherapy, principles and practice. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers. Chapter 20, p 485-92.
17. Ertel IJ, Nesbit ME, Hammond D, et al. 1979. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res, 39:3893-6.
18. Gaynon PS. 2005. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol, 131:579-87.
19. Goody HE, Ellem KA.1975. Nutritional effects on precursor uptake and compartmentalization of intracellular pools in relation to RNA synthesis. Biochim Biophys Acta, 383:30-9.
20. Hawkins DS, Park JR, Thomson BG, et al. 2004. Asparaginase Pharmacokinetics following intensive polyethylene glycol conjugated L-asparaginase (PEG-ASNase) therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res, 10:5335-41.
21. Holcenberg JS, Teller DC. 1976. Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A. J Biol Chem, 251:5375-80.
22. Jamieson CH, Ailles LE, Dylla SJ, et al. 2004. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med, 351:657-67.
23. Jarrar M, Gaynon PS, Periclou AP, et al. 2006. Asparagine depletion after pegylated E. Coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Cancer Group study (CCG-1941). Pediatr Blood Cancer, 47:141-6.
24. Khan A, Hill JM. 1971. Atopic hypersensitivity to L-asparaginase. Resistance to immunosuppression. Int Arch Allergy Appl Immunol, 40:463-9.
25. Kidd JG. 1953. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum or rabbit serum. J Exptl Med, 98:565-82.
26. Klug-Albertsen B, Schmiegelow K, Schroder H, et al. 2002. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study. Cancer Chemother Pharmacol, 50:117-20.
27. Kurtzberg J, Asselin B, Poplack D, et al. 1993. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy [abstract]. Proceedings of the 34th Annual Meeting of the American Association for Cancer Research. A1807.
28. Lubkowski J, Palm GJ, Gilliland GL, et al. 1996. Crystal structure and amino acid sequence of Wolinella succinogenes L-asparaginase. Eur J Biochem, 241:201-7.
29. McLean SR, Gana-Weisz M, Hartzoulakis B, et al. 2005. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther, 4:2008-15.
30. Mashburn LT, Wriston JC. 1964. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biocem, 105:451-2.
31. Novak EK, Philips AW. 1974. L-Glutamine as a substrate for L-asparaginase from Serratia marcescens. J Bacteriol, 117:593-600.
32. Oettgen HF, Old LJ, Boyse HA, et al. 1967. Inhibition of leukemias in man by L-asparaginase. Cancer Res, 27:2619-31.
33. Panosyan EH, Grigorian RS, Avramis IA, et al. 2004. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res, 24:1121-6.
34. Panosyan E, Avramis IA, Seibel NL, et al. 2002. Glutamine (Gln) deamination by asparaginases (ASNases) in children with higher risk acute lymphoblastic leukemia (HR ALL), (CCG-1961 study) [abstract]. Blood, 100:759a, nr 3006.
35. Pui CH, Pei D, Sandlund JT, et al. 2005. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol, 23:7936-41.
36. Robak T. 2005. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies. Drugs Aging, 22:983-1012.
37. Schwartz JH, Reeves JY, Broome JD. 1966. Two L-asparaginases from E. coli and their action against tumors. Proc Natl Acad Sci U S A, 56:1516-19.
38. Shama G, Bhagwat R, Pai SK, et al. 2005. Isolated testicular relapse in acute lymphoblastic leukemia-effective treatment with the modified CCG-112 protocol. Indian J Cancer, 42:65-9.
39. Silverman LB, Gelber RD, Dalton VK, et al. 2001. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood, 97:1211-18.
40. Sobin LH, Kidd JG. 1965. A metabolic difference between two lines of lymphoma 6C3HED cells in relation to asparagine. Proc Soc Exp Biol Med, 119:325-7.
41. Sobin LH, Kidd JG. 1966a. The incorporation of l-asparagine-14C by lymphoma 6C3HED cells: its inhibition by guinea pig serum. Cancer Res, 26:208-11.
42. Sobin LH, Kidd JG. 1966b. Alterations in protein and nucleic acid metabolism of lymphoma 6C3HED-og cells in mice given guinea pig serum. J Exp Med, 123:55-74.
43. Stern ML, Phillips AW, Gottlieb AJ. 1976. Physical properties of L-asparaginase from Serratia marcescens. J Bacteriol, 125:719-27).
44. Wade HE, Elsworth R, Herbert D, et al. 1968. A new L-asparaginase with anti-tumor activity. Lancet, 2:776-7.
45. Weiss RB. 1982. Hypersensitivity reactions to cancer chemotherapy. Semin Oncol, 9:5-12.